封面
市場調查報告書
商品編碼
1395945

心臟標記測試市場:規模、細分市場、份額、監管、報銷、到 2033 年的預測

Cardiac Marker Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2033

出版日期: | 出版商: GlobalData | 英文 | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

心臟標記檢測可測試疑似或已有ACS 或HF 患者的某些心臟標記水平,如肌鈣蛋白、腦鈉□(BNP) 和肌酸激□心肌帶(CK-MB)。用於確定是否患有ACS 或HF。正在上升或下降。 肌鈣蛋白通常被認為是 ACS 的黃金標準心臟標記物,並且往往被納入所有測試策略中。 然而,在美國,肌鈣蛋白和 CK-MB 的組合是最常見的測試方法。 最後,大多數心臟標記檢測方案往往包括三個(而不是兩個)時間點,特別是 CK-MB。 除了肌鈣蛋白和 CK-MB 之外,還可以對 ACS 患者進行 BNP 和 NT-proBNP 檢測。 因為多項臨床研究表明,BNP 和 NT-proBNP 可預測患者死亡率和長期臨床結果。

心臟標記檢測模型包括肌鈣蛋白檢測、肌鈣蛋白臨床檢測、肌鈣蛋白POC檢測、腦鈉尿□(BNP)檢測、腦鈉尿□(BNP)臨床檢測、腦鈉□(BNP )POC等測試、肌酸激□心肌帶 (CK-MB) 測試和其他心臟標記 POC 測試(CK-MB POC 測試、包括肌鈣蛋白、BNP 和 CK-MB 的心臟組合測試)。

本報告深入探討了全球心臟標記檢測市場,包括競爭格局、SWOT 分析、至 2033 年的市場預測、COVID-19 的影響、區域和國家趨勢等。我是。

目錄

目前心臟標記測試和競爭格局

  • 對主要產業趨勢的見解
  • 2015 年至 2033 年心臟標記測試各細分市場的市場總收入及市場前景
  • 有關數量、平均售價和市場價值的詳細數據

全球、區域與國家見解

  • 心臟標記檢測市場的SWOT分析
  • 心臟標記測試市場的競爭動態洞察與趨勢
  • 各國醫療保健系統概覽
  • 按國家/地區劃分的報銷政策
  • 各國醫療科技的監管狀況
簡介目錄

Abstract

Cardiac Marker Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Cardiac Marker tests market for the year 2020 and beyond. Cardiac Marker testing is used to determine whether levels of specific cardiac markers such as troponin, brain natriuretic peptide (BNP), or creatine kinase - myocardial band (CK-MB) have risen or fallen in suspected and/or existing ACS and HF patients. In general, troponin is considered the gold-standard Cardiac Marker for ACS and tends to be incorporated into all testing strategies. Despite this however, a combination of troponin and CK-MB remains the most common testing strategy employed in the US. Finally, most Cardiac Marker testing protocols tend to include three (not two) timepoints, especially those that include CK-MB. In addition to troponin and CK-MB, BNP and NT-proBNP tests are also sometimes performed in ACS patients as several clinical studies have indicated that they are predictive of patient mortality and long-term clinical outcome.

Cardiac Marker Tests model include Troponin Tests, Troponin Laboratory Tests, Troponin Point of Care (POC) Tests, Brain Natriuretic Peptide (BNP) Tests, Brain Natriuretic Peptide (BNP) Laboratory Tests, Brain Natriuretic Peptide (BNP) Point of Care (POC) Tests, Creatine Kinase - Myocardial Band (CK-MB) Tests and Other Cardiac Marker POC tests (CK-MB POC tests and Cardiac Panel tests which include troponin, BNP, or CK-MB) as sub-segments.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Cardiac Marker Tests and evolving competitive landscape:

  • Insightful review of the key industry trends.
  • Annualized total Cardiac Marker Tests market revenue by segment and market outlooks from 2015-2033.
  • Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
  • SWOT analysis for Cardiac Marker Tests market.
  • Competitive dynamics insights and trends provided for Cardiac Marker Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Quidelortho Corp, F. Hoffmann-La Roche Ltd, Siemens AG, bioMerieux SA, Danaher Corp, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

  • CMO executives who must have deep understanding of the Cardiac Marker Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

  • Understand the impact of COVID-19 on Cardiac Marker Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Cardiac Marker Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Cardiac Marker Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Cardiac Marker Tests market from 2015-2033.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.